Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Mediar Therapeutics

Request full access

Preclinical stage biotech company developing medicines to halt, or even reverse, fibrosis

Cambridge, United StatesFounded 2019Biotech & Life Sciences

About Mediar Therapeutics

Mediartx.com, operating under the name Mediar, is a biotech startup that is breaking new ground in the treatment of fibrosis, a disease characterized by the thickening and scarring of connective tissue. The company's unique approach targets fibrotic mediators, which are key drivers of disease progression, offering a new perspective and renewed hope for patients.

Mediar's market is primarily in the healthcare and pharmaceutical industry, specifically in the area of fibrosis treatment. The company serves a broad range of clients, including healthcare providers, patients suffering from fibrosis, and other stakeholders in the healthcare sector.

The business model of Mediar is based on the research, development, and commercialization of innovative fibrosis treatments. The company's team of industry-leading researchers leverages their deep expertise in fibrosis, antibody engineering, and translational science to accelerate clinical proof-of-concept studies. This approach allows Mediar to create and patent unique treatments, which are then sold or licensed to healthcare providers or pharmaceutical companies.

In terms of revenue generation, Mediar makes money through the sale or licensing of its patented treatments. The company also likely seeks funding from investors who are interested in the biotech industry and see the potential in Mediar's innovative approach to fibrosis treatment.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2019
Headquarters
Cambridge, United States
Employees
54
Open positions
None listed
Dealroom signal
78.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jan 2026 $76M $425M Longwood Fund · Alexandria Equities · Crystal IS · Intermediate Capital Group ↗
SERIES AOther financing Mar 2023 $85M $340M Bristol-Myers Squibb · Pfizer Ventures · Pureos Bioventures · Mission BioCapital ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Mediar Therapeutics website traffic

Latest recorded traffic for Mediar Therapeutics is 5.2K monthly website visits, up 116.7% over the last three months. Mediar Therapeutics's team grew 8% over the past year.

Latest monthly visits5.2K 3-month web change+116.7% 1-year team growth+8%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Mediar Therapeutics in the Cambridge ecosystem

Live from Dealroom

The Mediar Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

19 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed4 investors entered at this stage

  • Ono Venture Investment
  • Agent Capital
  • Mission BioCapital
  • Ono Pharmaceutical

Series A13 investors entered at this stage

  • Sofinnova Partners
  • Novartis Venture Fund
  • Bristol-Myers Squibb
  • Pfizer Ventures
  • Pureos Bioventures
  • Gimv
  • Eli Lilly
  • Mass General Brigham Ventures
  • Intermediate Capital Group
  • Amplitude Ventures
  • Longwood Fund
  • Alexandria Equities
  • Crystal IS

Other known investors2 additional known investors

  • Brigham and Women's Hospital
  • Massachusetts General Hospital
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇺🇸 United States83.7%
🇨🇭 Switzerland7%
🇬🇧 United Kingdom4.7%
🇨🇦 Canada2.3%
🇩🇪 Germany2.3%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Mediar Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Mediar Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.